Derivation and validation of a novel score for early prediction of severe CRS after CAR‐T therapy in haematological malignancy patients: A multi‐centre study
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18873 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Linghui Zhou und 24 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sanming Project of Medicine in Shenzhen.
Abstract (Originalsprache)
Chimeric antigen receptor T (CAR‐T) cell therapy is highly effective in inducing complete remission in haematological malignancies. Severe cytokine release syndrome (CRS) is the most significant and life‐threatening adverse effect of this therapy. This multi‐centre study was conducted at six hospitals in China. The training cohort included 87 patients with multiple myeloma (MM), an external validation cohort of 59 patients with MM and another external validation cohort of 68 patients with acute lymphoblastic leukaemia (ALL) or non‐Hodgkin lymphoma (NHL). The levels of 45 cytokines on days 1–2 after CAR‐T cell infusion and clinical characteristics of patients were used to develop the nomogram. A nomogram was developed, including CX3CL1, GZMB, IL4, IL6 and PDGFAA. Based on the training cohort, the nomogram had a bias‐corrected AUC of 0.876 (95% CI = 0.871–0.882) for predicting severe CRS. The AUC was stable in both external validation cohorts (MM, AUC = 0.907, 95% CI = 0.899–0.916; ALL/NHL, AUC = 0.908, 95% CI = 0.903–0.913). The calibration plots (apparent and bias‐corrected) overlapped with the ideal line in all cohorts. We developed a nomogram that can predict which patients are likely to develop severe CRS before they become critically ill, improving our understanding of CRS biology, and may guide future cytokine‐directed therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
- Institute of Hematology, Zhejiang University, Hangzhou, China.
- Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.
- Department of Hematology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Hematology, The Dingli Clinical College of Wenzhou Medical University (The Second Affiliated Hospital of Shanghai University, Wenzhou Central Hospital), Zhejiang, China.
ORCID-Profile: Kailin Xu, Xiaojing Yan, Jian Yu, Ying Wang, Yongxian Hu, He Huang
Förderung
- National Natural Science Foundation of China
- Sanming Project of Medicine in Shenzhen
Zitieren
APA
Zhou, L., Fu, W., Wu, S., Xu, K., Qiu, L., Xu, Y., Yan, X., Zhang, Q., Zhang, M., Wang, L., Hong, R., Chang, A. H., Yu, J., Fu, S., Kong, D., Li, L., Wang, Y., Li, Z., Jiang, H., …, & Huang, H. (2023). Derivation and validation of a novel score for early prediction of severe CRS after CAR‐T therapy in haematological malignancy patients: A multi‐centre study. British Journal of Haematology. https://doi.org/10.1111/bjh.18873
Vancouver
Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, et al. Derivation and validation of a novel score for early prediction of severe CRS after CAR‐T therapy in haematological malignancy patients: A multi‐centre study. British Journal of Haematology. 2023. doi:10.1111/bjh.18873
BibTeX
@article{Zhou2023,
author = {Zhou, Linghui and Fu, Weijun and Wu, Shenghao and Xu, Kailin and Qiu, Lugui and Xu, Yang and Yan, Xiaojing and Zhang, Qing and Zhang, Mingming and Wang, Linqin and Hong, Ruimin and Chang, Alex H and Yu, Jian and Fu, Shan and Kong, Delin and Li, Lu and Wang, Ying and Li, Zhenyu and Jiang, Huawei and Huang, Jing and Liu, Zhi and Su, Na and Wei, Guoqing and Hu, Yongxian and Huang, He},
title = {Derivation and validation of a novel score for early prediction of severe CRS after CAR‐T therapy in haematological malignancy patients: A multi‐centre study},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18873}
}
EUVIMED